PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Dermatitis, Seborrheic”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1992

Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis.

BACKGROUND: Previous studies have suggested that Pityrosporum yeasts may be important in the pathogenesis of seborrheic dermatitis (SD). SD occurs more frequently and has a different clinical appearance in patients who are human immunodeficiency virus (HIV)-seropositive than in HIV-seronegative patients. OBJECTIVE: Our purpose was to investigate the role of Pityrosporum yeasts in the pathogenesis of seborrheic dermatitis in HIV-seropositive patients. METHODS: Twenty-eight HIV-seropositive patients, including seven patients with SD and 21 without SD, and 20 HIV-seronegative patients with SD (n = 10) and without SD (n = 10) were investigated. Quantitative Pityrosporum cultures were taken from the face, chest, and back. RESULTS: None or only a small amount of Pityrosporum yeasts were cultured from SD lesions and SD predilection sites in HIV-seropositive patients. From the SD lesions in the HIV-seronegative control group large amounts of Pityrosporum yeasts were cultured. CONCLUSION: The results of this and other studies suggest that Pityrosporum yeasts play no role in SD in HIV-seropositive patients and that SD in these patients is a distinct entity to be separated from "classical" SD in HIV-seronegative patients.

Adult↗
PubMedDate not supplied

Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial.

BACKGROUND: The first gel formulation of ketoconazole has been tested in 2-week treatment courses. OBJECTIVE: To evaluate the efficacy and safety of a new, once-daily, 2-week ketoconazole 2% gel treatment in moderate to severe seborrheic dermatitis. METHODS: Four hundred fifty-nine subjects with moderate to severe seborrheic dermatitis were randomized to receive ketoconazole 2% gel or vehicle gel once daily for 14 days. The primary efficacy was the proportion of successfully treated subjects at day 28 (cleared and almost cleared). RESULTS: A significantly greater percentage of subjects were successfully treated with ketoconazole 2% gel compared with vehicle (25.3% vs. 13.9%, P = .0014). Ketoconazole 2% gel improved erythema, scaling (P = .0022 vs. vehicle), and pruritus. Mean overall symptom severity was reduced by 53% and 39% with ketoconazole gel and vehicle, respectively. Adverse events were few, generally mild or moderate, and similar between treatment groups. CONCLUSION: Once-daily ketoconazole 2% gel is an effective,well-tolerated, convenient, and cosmetically acceptable treatment for moderate to severe seborrheic dermatitis.

Administration, Topical↗
PubMed2004

Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial.

BACKGROUND: Seborrheic dermatitis is a common inflammatory skin disorder affecting 1-3% of the population. It is thought to be linked to dandruff via a common etiology, yeasts of the genus Malassezia. Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent with anti-inflammatory properties. METHODS: A total of 203 patients were enrolled in this vehicle-controlled, double-blind, randomized study designed to compare vehicle with three different concentrations of ciclopirox shampoo: 0.1%, 0.3% and 1%, with each applied twice a week. The main efficacy parameters were based on 6-point ordinal scales describing the disease's signs and symptoms (scaling, inflammation and itching), global status of disease, and global change in disease. RESULTS: A tendency towards improvement of the sum score from baseline was found in all ciclopirox treatment groups. The most pronounced improvement was found in the ciclopirox 1% group, which changed from a baseline sum score of 8.3 to 4.4 at the end of the 4-week study period (P-value vs. vehicle 0.0372). In addition, the therapeutic index showed increasing efficacy with the use of increased concentrations of ciclopirox. CONCLUSIONS: The study supports the use of 1% ciclopirox shampoo in the treatment of seborrheic dermatitis of the scalp. Furthermore, ciclopirox shampoo at each concentration was found to be safe and well tolerated.

Administration, Cutaneous↗